508 related articles for article (PubMed ID: 15491706)
1. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
[TBL] [Abstract][Full Text] [Related]
2. Prostatic phyto-oestrogen tissue levels in different Austrian regions.
Brössner C; Petritsch K; Fink K; Auprich M; Ponholzer A; Madersbacher S; Adlercreutz H; Petritsch P
Urol Int; 2006; 76(4):327-31. PubMed ID: 16679834
[TBL] [Abstract][Full Text] [Related]
3. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
4. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
5. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy.
Kurhanewicz J; Vigneron DB; Nelson SJ; Hricak H; MacDonald JM; Konety B; Narayan P
Urology; 1995 Mar; 45(3):459-66. PubMed ID: 7533458
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
7. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma.
Kim ED; Smith ND; Grayhack JT
J Urol; 1995 Nov; 154(5):1802-5. PubMed ID: 7563351
[TBL] [Abstract][Full Text] [Related]
9. Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.
Tokmadžić VS; Tomaš MI; Sotošek S; Laškarin G; Dominović M; Tulić V; Dorđević G; Sustić A; Mrakovčić-Šutić I
Scand J Immunol; 2011 Oct; 74(4):368-76. PubMed ID: 21535078
[TBL] [Abstract][Full Text] [Related]
10. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue.
Du Z; Fujiyama C; Chen Y; Masaki Z
Chin Med J (Engl); 2003 Dec; 116(12):1936-9. PubMed ID: 14687488
[TBL] [Abstract][Full Text] [Related]
11. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia.
Hong SJ; Kim SI; Kwon SM; Lee JR; Chung BC
Yonsei Med J; 2002 Apr; 43(2):236-41. PubMed ID: 11971218
[TBL] [Abstract][Full Text] [Related]
13. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
14. Disturbed homeostasis of zinc and other essential elements in the prostate gland dependent on the character of pathological lesions.
Sapota A; Darago A; Taczalski J; Kilanowicz A
Biometals; 2009 Dec; 22(6):1041-9. PubMed ID: 19629715
[TBL] [Abstract][Full Text] [Related]
15. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
16. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
17. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate.
Tiniakos DG; Mitropoulos D; Kyroudi-Voulgari A; Soura K; Kittas C
Urology; 2006 Jan; 67(1):204-8. PubMed ID: 16413376
[TBL] [Abstract][Full Text] [Related]
19. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden).
Hedelin M; Klint A; Chang ET; Bellocco R; Johansson JE; Andersson SO; Heinonen SM; Adlercreutz H; Adami HO; Grönberg H; Bälter KA
Cancer Causes Control; 2006 Mar; 17(2):169-80. PubMed ID: 16425095
[TBL] [Abstract][Full Text] [Related]
20. Prostate tissue and leukocyte levels of n-3 polyunsaturated fatty acids in men with benign prostate hyperplasia or prostate cancer.
Christensen JH; Fabrin K; Borup K; Barber N; Poulsen J
BJU Int; 2006 Feb; 97(2):270-3. PubMed ID: 16430627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
